Autoimmune Therapeutics in 2026–2029: B-Cell Targeting, FcRn Inhibitors, and CAR-T Driving a New Era of Business Development

Introduction

Autoimmune diseases affect 5–10% of the global population and have long lacked curative therapies. Over the past decade, cytokine-neutralizing biologics and JAK inhibitors transformed the landscape, yet most patients remain on chronic maintenance therapy. Three converging modalities—B-cell targeting therapies, neonatal Fc receptor (FcRn) inhibitors, and chimeric antigen receptor T-cell (CAR-T) and broader cell therapies—now represent the sector's most active engines of licensing, mergers and acquisitions (M&A), and pipeline repricing. This review synthesizes current clinical evidence and transaction data to orient medical professionals toward the 2026–2029 business development (BD) outlook.

Clinical and Mechanistic Rationale

B-cell targeting therapies exploit B cells' multifaceted pathogenic roles: autoantibody production, antigen presentation, T-cell co-stimulation, and pro-inflammatory cytokine secretion. CD20-directed antibodies (e.g., rituximab, obinutuzumab, ocrelizumab) cause rapid peripheral B-cell depletion but exert limited effects on long-lived plasma cells. CD19-targeting extends coverage to earlier B-cell precursors and certain plasma cell populations. BAFF/APRIL pathway blockade (belimumab, ianalumab) takes a more selective approach, suppressing B-cell survival signals while preserving residual humoral immunity 7. The clinical implication is that B-cell depletion is not a single, uniform strategy; mechanism of depletion, B-cell subset coverage, and plasma cell impact differ substantially across agents and directly inform BD valuations.

FcRn inhibitors act by blocking the neonatal Fc receptor that normally rescues IgG from lysosomal degradation, thereby accelerating IgG catabolism. The key mechanistic advantage is speed: IgG levels can fall within days to weeks without directly depleting B cells or plasma cells, preserving much of the cellular immune architecture 8. This mechanism is particularly well-suited to antibody-mediated diseases such as generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and pemphigus. The trade-off is predictable, dose-dependent hypogammaglobulinemia, necessitating monitoring of total IgG, vaccine responses, and infection risk.

CAR-T and cell therapies offer the most radical mechanistic proposition: a single course of CD19-targeted CAR-T cells may induce deep, potentially durable B-cell depletion, followed by regeneration of a naïve B-cell repertoire—conceptualized as "immune reset." Preclinical data in lupus-prone mice demonstrated complete and persistent B-cell depletion, autoantibody elimination, reversal of organ pathology, and extended survival; transferred T cells from treated animals conferred protection in naïve recipients, suggesting a durable, cell-mediated mechanism 9. In humans, early-phase data show that the majority of patients across systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathy (IIM) cohorts discontinue all chronic immunosuppression, with 94% of evaluable patients remaining off therapy at the time of analysis 20. Immune reconstitution data indicate CD8+ T cells recover earliest (median day 21), CD19+ B cells normalize around day 79, while IgG recovery can take 6 months or longer 12. These dynamics carry direct implications for infection risk management and retreatment strategy.

BD and Deal-Making Landscape

The financial scale of recent transactions underscores the sector's strategic priority. In 2024 alone, 33 licensing collaborations totaled $1.30 billion in value ($800 million in upfront payments), a 50% increase over 2023, alongside 11 M&A deals worth $1.16 billion 2. By 2025, autoimmune/immunology transactions ranked second only to oncology, comprising 106 deals (17% of total) versus 76 deals in 2024, with aggregate deal value of approximately $48 billion across 29 major transactions 21.

Table 1: Representative BD Transactions (2024–2026)

Several structural trends are discernible. First, platform-level acquisitions command the highest valuations: in vivo CAR-T platforms (AbbVie/Capstan at $2.1B, Lilly/Orna at $2.4B, BMS/Orbital at $1.5B) together exceeded $6B in aggregate, reflecting the strategic premium for scalable delivery technologies over single-product assets 21. Second, China-originated assets entering global markets are a defining feature of the current cycle—telitacicept's ex-China deal (up to $4.0B), UCB/Antengene ($1.18B), and Deerfield/METiS ($180M) collectively signal that Chinese biotech innovation in autoimmune biologics is now globally competitive 3521. Third, late-stage de-risked programs with multi-indication potential (e.g., ianalumab for Sjögren's and ITP) attract premium multiples because regulatory clarity reduces binary risk.

Asset-Class Comparison

Table 2: Modality Comparison—B-Cell Therapies, FcRn Inhibitors, and CAR-T

Table 3: Representative Assets, Indications, and Clinical Maturity (as of July 2026)

Pipeline Repricing and Investment Implications

Clinical readouts are the primary repricing catalysts. For B-cell therapies, the clearest positive signals come from randomized Phase III data: inebilizumab achieved a statistically significant MG-ADL improvement of –4.2 versus –2.2 (difference –1.9, p<0.001) in gMG, and obinutuzumab demonstrated a 46.4% versus 33.1% complete renal response rate in lupus nephritis (adjusted difference 13.4%, p=0.0232) 16. These results—characterized by durable benefit, steroid reduction, and sustained response at 52 weeks—are precisely the profile that supports premium licensing and label-expansion valuations. Conversely, rituximab's Phase III failures in SLE (EXPLORER, LUNAR) serve as a persistent caution that B-cell depletion efficacy does not extrapolate uniformly across indications 16.

For FcRn inhibitors, ianalumab's positive Phase III outcomes in Sjögren's syndrome (NEPTUNUS-1 and NEPTUNUS-2) and ITP, combined with FDA Breakthrough Therapy Designation in January 2026, exemplify how regulatory milestones translate directly into valuation uplift 1819. The FcRn class is now projected to exceed $10 billion in market size, driven by multi-indication replication from gMG into pemphigus, ITP, SLE, and beyond 2.

For CAR-T, the Breakfree-1 update from Bristol Myers Squibb represents the most consequential single clinical dataset in the space: 94% of evaluable patients across SLE, SSc, and IIM remained off chronic immunosuppression at analysis; in SSc, a median +10% improvement in predicted FVC at 6 months was observed—an outcome not previously achieved by any other modality 20. This dataset triggered the most significant repricing of the autoimmune CAR-T landscape, validating the immune reset concept across multiple connective tissue diseases. However, all-grade CRS and transient ICANS events underscore that safety management remains non-negotiable, and the key repricing question is whether deep, durable responses can be achieved without unacceptable infection or neurological burden 1011.

Manufacturing scalability is an increasingly important valuation dimension. In vivo CAR-T platforms (AbbVie/Capstan, BMS/Orbital, Lilly/Orna) attracted a combined >$6B in acquisition value on the thesis that lipid nanoparticle (LNP)-mediated in vivo CAR programming can eliminate lymphodepletion, complex ex vivo manufacturing, and hospitalization requirements 621. Regulatory agencies—including FDA relaxation of certain autoimmune CAR-T guidance in 2025—are signaling openness to these approaches, though CMC characterization, long-term safety monitoring, and durability verification remain active requirements 2223.

Medical and Strategic Implications

These modalities collectively redefine treatment sequencing. A plausible 2026–2029 framework positions FcRn inhibitors as rapid-onset bridging or maintenance therapy in antibody-mediated diseases (gMG, ITP, pemphigus), B-cell targeting antibodies as foundational disease-modifying therapy across the SLE/LN/Sjögren's spectrum, and CAR-T as the intervention of last resort for refractory disease—or, as clinical confidence grows, as an earlier-line immune reset for selected severe cases. The steroid-sparing implication is clinically significant: rituximab in pemphigus demonstrated a 52-week complete sustained response of 40.3% versus 9.5% with corticosteroids alone (p<0.001), with lower cumulative steroid exposure 16; early CAR-T cohorts show nearly universal cessation of background immunosuppression.

Table 4: Value Drivers and Risk Factors by Modality (2026–2029)

Practical constraints must temper optimism. Hypogammaglobulinemia following CD19 CAR-T therapy develops in virtually all patients within 2 weeks of infusion; IgG recovery takes a median of 6 months, IgA recovery extends beyond 1 year 12. In the oncology experience with CD19 CAR-T, cumulative 1-year infection rates exceeded 60%, with severe bacterial infection in nearly 30% 11. Steroid use for CRS/ICANS management compounded infection risk. For autoimmune patients—who often carry baseline immune compromise from prior immunosuppressants—these data mandate rigorous immunoglobulin replacement protocols, infectious disease co-management, and standardized monitoring frameworks before broader implementation.

Conclusion

The 2026–2029 autoimmune therapeutics BD landscape is defined by the convergence of mechanistic innovation and unprecedented deal-making scale. B-cell targeting therapies offer the most broadly de-risked commercial base, with landmark Phase III readouts in gMG, lupus nephritis, and Sjögren's syndrome creating near-term licensing and label-expansion opportunities. FcRn inhibitors constitute the clearest platform play—multi-indication replication from established gMG approvals toward ITP, pemphigus, SLE, and beyond justifies the sector's growing premium valuations. CAR-T and cell therapies, led by Breakfree-1 data and an accelerating in vivo delivery platform wave, represent the modality with the highest repricing potential but also the most significant unresolved questions around durability, safety, manufacturing, and cost. China-originated assets are no longer peripheral to this landscape; they are central to global BD strategy, with cross-border transactions already reshaping how innovation flows between Chinese biotech ecosystems and global pharmaceutical platforms. For medical professionals engaged in clinical development or translational strategy, the critical evaluative lens for 2026–2029 is not whether these modalities work in principle—the mechanistic and early-phase evidence is compelling—but whether they can deliver durable, manageable, and accessible benefit at the scale that patients, payers, and health systems require.